.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,371,292

« Back to Dashboard

Claims for Patent: 8,371,292

Title:Use of ciclesonide for the treatment of respiratory diseases
Abstract: The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.
Inventor(s): Bethke; Thomas (Constance, DE), Engelstaetter; Renate (Allensbach, DE), Wurst; Wilhelm (Constance, DE)
Assignee: Nycomed GmbH (Constance, DE)
Application Number:10/571,311
Patent Claims: 1. A method for treating a respiratory disease in a child while reducing or avoiding systemic side effects on said child's growth rate, comprising administering to the child a dose of a composition containing ciclesonide as the sole active ingredient, or a pharmaceutically acceptable salt thereof, wherein the dose of the composition comprises ciclesonide in an amount of from 20 to 200 .mu.g, and wherein ciclesonide consists essentially of its R-epimer.

2. The method according to claim 1, wherein the dose comprises 20, 40, 60, 80, 100, 120, 140, 160, 180 or 200 .mu.g of ciclesonide.

3. The method according to claim 1, wherein the dose comprises 40, 80 or 160 .mu.g of ciclesonide.

4. The method according to claim 1, wherein the child is a pre-pubertal human.

5. The method according to claim 1, wherein the child is a human from 6 to 12 years of age.

6. The method according to claim 1, wherein the dose is a daily dose in a continuous treatment regimen.

7. The method according to claim 6, wherein the treatment period is more than one day.

8. The method according to claim 7, wherein the treatment period is more than one week.

9. The method according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier and/or one or more excipients.

10. The method according to claim 1, wherein the dose is administered once daily.

11. The method according to claim 1, wherein the composition is suitable for administration by inhalation.

12. The method according to claim 11 wherein the composition is a pharmaceutical aerosol formulation comprising a therapeutically effective amount of ciclesonide and a hydrofluorocarbon propellant and cosolvent in an amount effective to solubilize ciclesonide and optionally a surfactant.

13. The method according to claim 12, wherein the cosolvent is ethanol.

14. The method according to claim 11 wherein the composition is a pharmaceutical aerosol formulation comprising particles of ciclesonide in a therapeutically effective amount and a hydrofluorocarbon propellant and 0.01 to 5% w/w based upon propellant of polar cosolvent and optionally a surfactant.

15. The method according to claim 11 wherein the composition is a dry powder and the carrier is a saccharide.

16. The method according to claim 11 wherein the carrier is lactose monohydrate.

17. The method according to claim 1, wherein the respiratory disease is selected from the group consisting of asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD), chronic bronchitis, wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, rhinitis, and allergic and seasonal rhinitis.

18. The method according to claim 1, wherein the respiratory disease is mild or moderate asthma.

19. The method according to claim 12 wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

20. The method according to claim 14 wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

21. The method according to claim 1, wherein the composition is an intranasal spray or nasal drops.

22. The method according to claim 21, wherein the composition is an aqueous formulation for application to mucosa.

23. The method according to claim 21, wherein the composition is a non-aqueous formulation for application to mucosa.

24. The method according to claim 1, wherein the child is a human below the age of eighteen years.

25. The method according to claim 1, wherein the respiratory disease is rhinitis.

26. The method according to claim 1, wherein the respiratory disease is allergic rhinitis.

27. The method according to claim 1, wherein the respiratory disease is seasonal allergic rhinitis.

28. The method according to claim 1, wherein the amount of ciclesonide administered is a daily dose.

29. The method according to claim 2, wherein the amount of ciclesonide administered is a daily dose.

30. The method according to claim 3, wherein the amount of ciclesonide administered is a daily dose.

31. The method according to claim 1, wherein the dose is administered twice daily.

32. The method according to claim 11, 12, 13 or 14, wherein the composition is suitable for oral administration.

33. The method according to claim 11, 12, 13 or 14, wherein the composition is suitable for intranasal administration.

34. The method according to claim 26, wherein the composition is an aqueous intranasal spray, wherein the dose of the composition is administered once daily and comprises ciclesonide in an amount of 200 .mu.g.

35. The method according to claim 13, wherein the respiratory disease is asthma, and wherein the dose of the composition is administered orally twice daily and comprises ciclesonide in an amount of 80 .mu.g or 160 .mu.g.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc